Yang Huarong, Xing Haiyan, Zou Xue, Jin Meihua, Li Yang, Xiao Ke, Cai Li, Liu Yao, Yang Xue
Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China.
Department of Cardiovascular Medicine, Daping Hospital, Army Medical University, Chongqing, China.
Clin Exp Hypertens. 2025 Dec;47(1):2465399. doi: 10.1080/10641963.2025.2465399. Epub 2025 Feb 14.
To evaluate the efficacy and safety of intensive blood pressure control in patients over 60 years.
Databases including PubMed, Embase and Cochrane library were searched from inception through February 1, 2024. Randomized controlled trials evaluating the efficacy or safety of intensive blood pressure control in patients over 60 years were included in the meta-analysis.
Intensive blood pressure control in individuals with mild hypertension has been shown to reduce the risk of heart failure, stroke, myocardial infarction, major cardiovascular events, cardiovascular mortality, and all-cause mortality. The benefits of intensive blood pressure control in patients with moderate to severe hypertension are comparable to those observed in individuals with mild hypertension, with the exception of a reduced impact on all-cause mortality and cardiovascular mortality. Compared with maintaining systolic blood pressure (SBP) above 140 mmHg, SBP below 140 mmHg is associated with a decreased risk of major cardiovascular events in patients aged over 70, as well as a reduced risk of stroke in patients aged 60-69. Furthermore, compared to maintaining SBP above 130 mmHg, SBP below 130 mmHg is linked to a lower risk of major cardiovascular events, heart failure and myocardial infarction in patients over 60, a reduced risk of stroke and cardiovascular mortality in patients aged 60-69, and a decreased risk of all-cause mortality in patients over 70. However, a lower baseline blood pressure or more aggressive blood pressure control may be associated with an increased risk of hypotension.
Patients with hypertension aged over 60 years can derive benefits from intensive blood pressure management without experiencing significant adverse events, aside from hypotension.
评估60岁以上患者强化血压控制的疗效和安全性。
检索包括PubMed、Embase和Cochrane图书馆在内的数据库,检索时间从建库至2024年2月1日。纳入评估60岁以上患者强化血压控制疗效或安全性的随机对照试验进行荟萃分析。
已表明,轻度高血压患者强化血压控制可降低心力衰竭、中风、心肌梗死、主要心血管事件、心血管死亡率和全因死亡率的风险。中度至重度高血压患者强化血压控制的益处与轻度高血压患者相当,但对全因死亡率和心血管死亡率的影响较小。与收缩压(SBP)维持在140 mmHg以上相比,SBP低于140 mmHg与70岁以上患者主要心血管事件风险降低以及60-69岁患者中风风险降低相关。此外,与SBP维持在130 mmHg以上相比,SBP低于130 mmHg与60岁以上患者主要心血管事件、心力衰竭和心肌梗死风险降低、60-69岁患者中风和心血管死亡率降低以及70岁以上患者全因死亡率降低相关。然而,较低的基线血压或更积极的血压控制可能与低血压风险增加相关。
60岁以上高血压患者可从强化血压管理中获益,除低血压外,无明显不良事件发生。